Classes | Virtual Medical Academy

Viewing 24 results

You are viewing the category of Dermatology

Dermatology

Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment

By :

Prof.Vimal Prajapati

Dermatology

Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights

By :

Prof.Vimal Prajapati

Dermatology

Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights

By :

Prof.Vimal Prajapati

Dermatology

Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate

By :

Prof.Vimal Prajapati

Dermatology

Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

By :

Prof.Vimal Prajapati

Dermatology

Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

By :

Prof.Vimal Prajapati

Dermatology

How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

By :

Lilly Saudi Arabia

Dermatology

Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

By :

Lilly Saudi Arabia

Dermatology

Assessing Subjective Burden in Patients with Atopic Dermatitis

By :

Pro.Jonathan & Prof.Melinda

Dermatology

Assessing Clinical Severity in Patients with Atopic Dermatitis

By :

Pro.Jonathan & Prof.Melinda

Dermatology

Assessing lack of treatment response in patients with Atopic Dermatitis

By :

Pro.Jonathan & Prof.Melinda

Dermatology

Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

By :

Dr. Sarina Elmariah

About Us

Support

Technical Requirements

VMA Team

Partner

You are viewing the category of Dermatology

Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment

Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights

Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights

Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate

Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

Assessing Subjective Burden in Patients with Atopic Dermatitis

Assessing Clinical Severity in Patients with Atopic Dermatitis

Assessing lack of treatment response in patients with Atopic Dermatitis

Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

Call Center 920008161

[email protected]